*  Executive Dysfunction in Restless Legs Syndrome: Clinical Correlates and Outcome After Therapeutic Management - Full Text View ...
Taking any psychotropic medication within 15 days prior to polysomnography (except for patients on dopamine agonist reassessed ... The efficacy of dopaminergic agents in improvement of sensorimotor symptoms advance the hypothesis that altered dopaminergic ... RLS patients previously treated with a dopamine agonist who has not stopped treatment at least 15 days before the start of the ...
  https://clinicaltrials.gov/ct2/show/NCT01823354?recr=Open&cond=%22Restless+Legs+Syndrome%22&rank=9
*  Dopamine Side Effects in Detail - Drugs.com
Learn about the potential side effects of dopamine. Includes common and rare side effects information for consumers and ... Inotropic agents. Vasopressors. Related Drugs. Nonobstructive Oliguria furosemide, Lasix, torsemide, Demadex, dopamine, Edecrin ... Applies to dopamine: parenteral injection concentrate for iv infusion, parenteral injection for iv infusion ... Dopamine may cause cardiac conduction abnormalities (e.g., ventricular arrhythmia, atrial fibrillation, widened QRS complex, ...
  https://www.drugs.com/sfx/dopamine-side-effects.html
*  Torsion dystonia - Wikipedia
... dopaminergic agents/dopamine-depleting agents, and tetrabenazine. Each medication is started on a low dosage and gradually ...
  https://en.wikipedia.org/wiki/Torsion_dystonia
*  3,4-Methylenedioxyamphetamine - Wikipedia
Relative to MDMA, MDA is also a more potent releasing agent of norepinephrine and dopamine and hence is more stimulating in ... In terms of pharmacology, MDA acts most importantly as a serotonin-norepinephrine-dopamine releasing agent (SNDRA). Due to its ... and for these reasons acts as a reuptake inhibitor and releasing agent of serotonin, norepinephrine, and dopamine (that is, it ... release of dopamine and norepinephrine is responsible for its psychostimulant effects, dopamine release is necessary for its ...
  https://en.wikipedia.org/wiki/3,4-Methylenedioxyamphetamine
*  Trifluoromethylphenylpiperazine - Wikipedia
More commonly, TFMPP is co-administered with BZP, which acts as a norepinephrine and dopamine releasing agent. Due to the ... It has no effects on dopamine or norepinephrine reuptake or efflux. TFMPP is rarely used by itself. In fact, TFMPP reduces ... serotonin agonist effects and increase in serotonin, norepinephrine, and dopamine levels produced by the BZP/TFMPP combination ...
  https://en.wikipedia.org/wiki/Trifluoromethylphenylpiperazine
*  3-Fluorophenmetrazine - Wikipedia
3-FPM acts as a norepinephrine-dopamine releasing agent with EC50 values of 43 nM and 30 nM, respectively. It shows only ...
  https://en.wikipedia.org/wiki/3-Fluorophenmetrazine
*  Serotonin-dopamine reuptake inhibitor - Wikipedia
A closely related type of drug is a serotonin-dopamine releasing agent (SDRA). Relative to serotonin-norepinephrine-dopamine ... and inhibit the reuptake of dopamine alone. As a result, selective dopamine reuptake inhibitors (DRIs) are rare, and comparably ... A serotonin-dopamine reuptake inhibitor (SDRI) is a type of drug which acts as a reuptake inhibitor of the monoamine ... Based on its chemical structure, UWA-101 may actually also possess some activity as a releasing agent, and if so, unlike RTI-83 ...
  https://en.wikipedia.org/wiki/Serotonin%E2%80%93dopamine_reuptake_inhibitor
*  Dimethoxymethamphetamine - Wikipedia
It appears to act as a serotonin-norepinephrine-dopamine releasing agent (SNDRA), although it is significantly less potent than ...
  https://en.wikipedia.org/wiki/Dimethoxymethamphetamine
*  Serotonin releasing agent - Wikipedia
They act as serotonin-norepinephrine-dopamine releasing agents (SNDRAs) and also agonize serotonin receptors such as those in ... A serotonin releasing agent (SRA) is a type of drug that induces the release of serotonin into the neuronal synaptic cleft. A ... Scorza C, Silveira R, Nichols DE, Reyes-Parada M (July 1999). "Effects of 5-HT-releasing agents on the extracellullar ... Scorza C, Silveira R, Nichols DE, Reyes-Parada M (July 1999). "Effects of 5-HT-releasing agents on the extracellullar ...
  https://en.wikipedia.org/wiki/Serotonin_releasing_agent
*  Ortho-Methylphenylpiperazine - Wikipedia
It acts as a serotonin-norepinephrine-dopamine releasing agent (SNDRA), with EC50 values for induction of monoamine release of ... The 2,3-methyl and 4-methyl analogues show diminished activity as dopamine releasing agents with respective EC50 values of ... and chemical perspectives on atypical agents targeting the dopamine transporter". Drug Alcohol Depend. 147: 1-19. doi:10.1016/j ... to 13.9-fold preference for induction of norepinephrine release over dopamine. ...
  https://en.wikipedia.org/wiki/Ortho-Methylphenylpiperazine
*  Modafinil - Wikipedia
In addition, modafinil fails to reverse reserpine-induced akinesia, whereas dextroamphetamine, a dopamine releasing agent (DRA ... Of the sites tested, it was found to significantly affect only the dopamine transporter (DAT), acting as a dopamine reuptake ... and chemical perspectives on atypical agents targeting the dopamine transporter". Drug and Alcohol Dependence. 147: 1-19. doi: ... "Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications". Jama. 301 (11): ...
  https://en.wikipedia.org/wiki/Modafinil
*  Monoamine releasing agent - Wikipedia
Serotonin-dopamine releasing agent (SDRA) Serotonin-norepinephrine-dopamine releasing agent (SNDRA) MRAs cause the release of ... Dopamine releasing agent (DRA) Non-selective, releasing two or more neurotransmitters Norepinephrine-dopamine releasing agent ( ... Dopamine release agents, usually selective for both norepinephrine and dopamine have psychostimulant effect, causing an ... Less selective serotonergic agents that stimulate an efflux in dopamine, such as MDMA are described as more pleasant, ...
  https://en.wikipedia.org/wiki/Monoamine_releasing_agent
*  Dopamine antagonist - Wikipedia
MeSH list of agents 82018492 Dopamine antagonists at the US National Library of Medicine Medical Subject Headings (MeSH). ... A dopamine antagonist (antidopaminergic) is a type of drug which blocks dopamine receptors by receptor antagonism. Most ... Several other dopamine antagonists are antiemetics used in the treatment of nausea and vomiting. Dopamine receptor antagonists ... trimipramine Choline can antagonize dopamine directly or interfere with receptor function Melatonin suppresses dopamine ...
  https://en.wikipedia.org/wiki/Dopamine_antagonist
*  Tranylcypromine - Wikipedia
Compared to amphetamine, tranylcypromine shows low potency as a dopamine releasing agent, with even weaker potency for ... This leads to an increase in the availability of monoamines, such as serotonin, norepinephrine, and dopamine, as well as a ... It is used as an antidepressant and anxiolytic agent in the clinical treatment of mood and anxiety disorders, respectively. ... alternative agents are recommended. Other studies have come to similar conclusions. Pharmacokinetic interactions with ...
  https://en.wikipedia.org/wiki/Tranylcypromine
*  Iodobenzamide - Wikipedia
... a potential CNS D-2 dopamine receptor imaging agent". Nuclear Medicine and Biology. 15 (2): 195-201. doi:10.1016/0883-2897(88) ... Pharmaceutically it is a dopamine antagonist and it can be used by nuclear medicine physicians as a radioactive tracer for ... Kung, Hank, F.; Alavi; Chang; Kung; Keyes; Velchik; Billings; Pan; Noto (1990). "In vivo SPECT imaging of CNS D-2 dopamine ...
  https://en.wikipedia.org/wiki/Iodobenzamide
*  Pleurothotonus - Wikipedia
Acute dystonia nearly always develops a few weeks after a dopamine blocking agent/medication has begun or a substantial ... Tardive dykinesias have also been associated with polymorphism in the dopamine receptor D2 gene, dopamine receptor D3 gene, ... The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr Res ... Acute effects of dopamine antagonists also include Parkinsons-like symptoms, manifested by bradykinesia, pin rolling tremor, ...
  https://en.wikipedia.org/wiki/Pleurothotonus
*  AMPT - Wikipedia
... a dopamine-releasing agent, rapidly decreased vesicular uptake. A relationship between cytoplasmic dopamine concentration and ... AMPT's ability to deplete dopamine in the CNS makes it a promising target for treatment of dopamine related disorders. AMPT ... Reserpine causes almost full loss of dopamine from the striatum by disrupting vesicle storage. The repletion of dopamine after ... Dystonia and Dyskinesia- Dystonias and dyskinesias onset seems to derive from inconsistent regulation of dopamine in dopamine ...
  https://en.wikipedia.org/wiki/AMPT
*  Bupropion - Wikipedia
Bupropion is a norepinephrine-dopamine reuptake inhibitor (NDRI). It has also been found to act as a releasing agent of ... Bupropion inhibits the reuptake of dopamine through the human dopamine transporter and norepinephrine transporter; the ... Its effect may also be "considerably less than of the approved agents ... Thus it may be prudent for the clinician to recommend ... Bupropion is known to weakly inhibit the α1 adrenergic receptor, with a 14% potency of its dopamine uptake inhibition, and the ...
  https://en.wikipedia.org/wiki/Bupropion
*  Fenfluramine - Wikipedia
At high concentrations, norfenfluramine, though not fenfluramine, also acts as a dopamine releasing agent, and so fenfluramine ... The combination of fenfluramine with phentermine, a norepinephrine-dopamine releasing agent acting primarily on norepinephrine ... results in a well-balanced serotonin-norepinephrine releasing agent with weaker effects of dopamine release. The elimination ... The drug also acts as a norepinephrine releasing agent to a lesser extent, particularly via its active metabolite ...
  https://en.wikipedia.org/wiki/Fenfluramine
*  SB-277,011-A - Wikipedia
Joyce, JN; Millan, MJ (2005). "Dopamine D3 receptor antagonists as therapeutic agents". Drug Discovery Today. 10 (13): 917-25. ... SB-277,011A is a drug which acts as a potent and selective dopamine D3 receptor antagonist, which is around 80-100x selective ... Vorel, SR; Ashby Jr, CR; Paul, M; Liu, X; Hayes, R; Hagan, JJ; Middlemiss, DN; Stemp, G; Gardner, EL (2002). "Dopamine D3 ... Heidbreder, CA; Andreoli, M; Marcon, C; Hutcheson, DM; Gardner, EL; Ashby Jr, CR (2007). "Evidence for the role of dopamine D3 ...
  https://en.wikipedia.org/wiki/SB-277,011-A
*  Phenmetrazine - Wikipedia
Phenmetrazine acts as a releasing agent of norepinephrine and dopamine with EC50 values of 50.4 ± 5.4 nM and 131 ± 11 nM, ... is a releasing agent of dopamine and norepinephrine. The molecule also loosely resembles ethcathinone, the active metabolite of ... are mostly selective as noradrenaline releasing agents. Phenmetrazine has been used recreationally in many countries such as ...
  https://en.wikipedia.org/wiki/Phenmetrazine
*  Batanopride - Wikipedia
BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. Journal of Pharmacology and Experimental ...
  https://en.wikipedia.org/wiki/Batanopride
*  Amineptine - Wikipedia
It acts as a selective and mixed dopamine reuptake inhibitor and releasing agent, and to a lesser extent as a norepinephrine ... However, amineptine is much less efficacious as a dopamine releasing agent relative to D-amphetamine, and the drug appears to ... In contrast to the case for dopamine, amineptine does not induce the release of norepinephrine, and hence acts purely as a ... Amineptine inhibits the reuptake of dopamine and, to a much lesser extent, of norepinephrine. In addition, it has been found to ...
  https://en.wikipedia.org/wiki/Amineptine
*  Altropane - Wikipedia
Preparation and biological evaluation of iodine-125-IACFT: a selective SPECT agent for imaging dopamine transporter sites. ... It has mainly been used as the 125I radiolabelled form for mapping the distribution of dopamine transporters in the brain, and ... Further evidence of dopamine transporter dysregulation in ADHD: a controlled PET imaging study using altropane. Biological ... Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse. 1998 Jun ...
  https://en.wikipedia.org/wiki/Altropane
*  Serotonin-norepinephrine-dopamine reuptake inhibitor - Wikipedia
They are also very similar to serotonin-norepinephrine-dopamine releasing agents (SNDRAs) like MDMA ("ecstasy") and α- ... Rothman, RB; Blough, BE; Baumann, MH (2008). "Dual dopamine/serotonin releasers: Potential treatment agents for stimulant ... Tetrabenazine, a similar agent to reserpine, which also depletes catecholamine stores, and to a lesser degree 5-HT, was shown ... A serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI), also known as a triple reuptake inhibitor (TRI), is a type of ...
  https://en.wikipedia.org/wiki/Serotonin%E2%80%93norepinephrine%E2%80%93dopamine_reuptake_inhibitor